Hangzhou Zhongmei Huadong

Huadong Medicine, primarily operating through its subsidiary Hangzhou Zhongmei Huadong Pharmaceutical, is a leading Chinese pharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies. The company maintains a dominant position in the Chinese diabetes market and has aggressively expanded its portfolio into oncology, immunology, and nephrology through strategic global licensing deals. Notably, Huadong has established a significant presence in the antibody-drug conjugate (ADC) space and the medical aesthetics sector. With a robust commercial infrastructure and a growing pipeline of biosimilars and novel chemical entities, the company is transitioning from a traditional manufacturer to an innovation-led global healthcare player.